Vellykket registrering
Din registrering er satt på vent
Din konto er aktivert, men fordi vårt system ikke umiddlebart kunne gjenkjenne deg som helsepersonell må det gjøres en manuell sjekk. Du vil motta en e-post med resulatet i løpet av få dager.
I mellomtiden har du tilgang til alle tjenester på portalen.
Severe Eosinophilic Asthma (SEA)
Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Nucala in 4 eosinophilic diseases
Nucala is the anti-IL-5 therapy that is approved for the treatment of 4 eosinophilic diseases.1
Since March 2016 Nucala has been approved as an add-on treatment for SEA (severe eosinophilic asthma) in adults, adolescents and children aged 6 years and older. At the end of 2021 (November 2021) Nucala has also been approved for 3 other eosinophilic diseases in Norway: CRSwNP (chronic rhinosinusitis with nasal polyps), EGPA (eosinophilic granulomatosis with polyangiitis) and HES (hypereosinophilic syndrome).1
For relevant scientific information on each indication, click on the button.
Nucala (mepolizumab, 100 mg, 40 mg) for subcutaneous injection once every 4 weeks (pre‑filled pen 100 mg, pre‑filled syringe 40 mg and 100 mg) is indicated in:
Severe asthma (SA), as add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Chronic Rhinosinusitis with Nasal Polyps (CRSwNP), as add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe chronic rhinosinusitis with nasal polyps for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.
Eosinophilic Granulomatosis with polyangiitis (EGPA), as add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis.
Hypereosinophilic Syndrome (HES), as add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without any identifiable non-haematologic secondary cause.
SELECTED SAFETY INFORMATION
Warnings and precautions:
Should not be used to treat acute asthma exacerbations. Patients should be advised to seek medical attention if their asthma remains uncontrolled or worsens after starting treatment. Abrupt discontinuation of corticosteroids after initiation of treatment is not recommended.
Allergic reactions:
Acute and delayed systemic reactions, including hypersensitivity reactions, have occurred. Patients should be instructed to seek immediate medical attention if allergic reactions occur. Appropriate treatment should be initiated in the event of a hypersensitivity reaction.
Parasitic infections:
Pre‑existing helminth infections should be treated before initiating therapy. If a patient becomes infected during Nucala treatment and does not respond to anti‑helminth therapy, temporary discontinuation of Nucala should be considered.
Organ‑threatening or life‑threatening manifestations of EGPA and HES:
These have not been studied.
Adverse reactions:
In clinical studies in patients with severe refractory eosinophilic asthma and EGPA, headache, injection‑site reactions, and back pain were the most commonly reported adverse reactions during treatment.
In patients with CRSwNP: headache and back pain.
In patients with HES: headache, urinary tract infection, injection‑site reactions, and pyrexia.
Adverse events should be reported to GlaxoSmithKline on 22 70 20 00. Read the prescribing information before prescribing Nucala.
Reseptgruppe C.
Finansiering: H-resept: R03D X09_1 Mepolizumab.
Der det er utarbeidet nasjonale handlingsprogrammer/nasjonal faglig retningslinje og/eller anbefalinger fra RHF/LIS spesialistgruppe skal rekvirering gjøres i tråd med disse. Vilkår: 216 Refusjon ytes kun etter resept fra sykehuslege eller avtalespesialist.
Maksimalpriser: 100 mg 1 stk ferdigfylt penn/sprøyte 13587,10 kr. 40 mg 1 stk ferdigfylt sprøyte 5537,80kr.
Avtalepris inngår i Sykehusinnkjøp anbud Alvorlig ukontrollert T2-høy astma fra 01.09.2024. Anbudet inneholder rabatterte priser.
Nucala (mepolizumab) er besluttet innført av Beslutningsforum til behandling av alvorlig eosinofil astma, kronisk rhinosinusitt med nasal polypose (CRSwNP) og hypereosinofilt syndrom (HES).
References
©2026 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.
PM-NO-MPL-WCNT-260001 February 2026
